Giuseppe Di Lucca

Specialty:

Hematology Internal Medicine Oncology

Profession:

Hematologist

Languages:

Do you need an appointment?

Secure your spot with the doctor

View doctor availability

Send request

Biography

Dr. Giuseppe Di Lucca is an oncologist and hematologist at the General Medicine and Advanced Care Unit of IRCCS Ospedale San Raffaele, directed by Dr. Moreno Tresoldi.

He graduated in Medicine and Surgery from the University of Milan in 1986 and later specialized in Oncology (1989) and Hematology (1999) at the same university.

Clinically, Dr. Di Lucca serves as a senior attending physician and is responsible for the "Choosing Wisely" project. He supervises the management of complications in hospitalized patients with oncological and onco-hematological diseases. With over 20 years of experience in oncology, he has extensive expertise in diagnosing and treating various malignancies, particularly genitourinary cancers (kidney, bladder, testicular, and prostate tumors) and lymphomas (Hodgkin and non-Hodgkin).

In recent years, his focus has been on tumor immunotherapy with checkpoint inhibitors, with a specific interest in the diagnosis and treatment of immune-mediated toxicities. Since October 2020, he has also been responsible for the COVID-19 inpatient care unit at San Raffaele Turro.

Dr. Di Lucca is the author and co-author of numerous publications in national and international scientific journals, as well as book chapters. He regularly participates as a speaker at national and international scientific conferences.

Publications

Latest publications

Autoimmune thyroiditis following interleukin-2 and LAK cell therapy for metastatic renal cell carcinoma: correlation with tumor regression

Tumori 1991; 77:339-341.

Besana C, Sabbadini MG, Corti C, Di Lucca G, Foppoli M, Marcatti M, Heltai S, Rugarli C.

Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alphainterferon

Eur J Cancer 1994; 30A:1292-1298

Besana C, Borri A, Bucci E, Citterio G, Di Lucca G, Fortis C, Matteucci P, Tognella S, Tresoldi M, Baiocchi C, Landonio G, Ghislandi E, Rugarli C.

Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2

Br J Cancer 1996; 74: 1297-1301

Citterio G, Pellegatta F, Di Lucca G, Fragasso G, Scaglietti U, Pini D, Fortis C, Tresoldi M, Rugarli C.

Isolated left ventricular filling abnormalities may predict interleukin-2-induced cardiovascular toxicity

J Immunother 1996; 19: 134-141

Citterio G, Fragasso G, Rossetti E, Di Lucca G, Bucci E, Foppoli M, Guerrieri R, Matteucci P, Polastri D, Scaglietti U, Tresoldi M, Chierchia SL, Rugarli C.

Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients

Eur Urol 1997; 31: 286-291

Citterio G, Bertuzzi A, Tresoldi M, Galli L, Di Lucca G, Scaglietti U, Rugarli C.

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

Lung Cancer 2011; 73: 78-88

Banna GL, Di Maio M, Follador A et al. (co-authors: Airoldi M,…..Di Lucca G….)

Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study

Invest New Drugs 2012; 30: 1978-1983

Rosati G, Cordio S, Aprile G, Butera A, Avallone A, Di Lucca G, De Pauli F, Parra HS, Reggiardo G, Bordonaro R.

Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial

Eur J Cancer. 2013;49(17):3609-15.

Reni M, Cereda S, Milella M, Novarino A, Passardi A, Mambrini A, Di Lucca G, Aprile G, Belli C, Danova M, Bergamo F, Franceschi E, Fugazza C, Ceraulo D, Villa E.

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Lancet Oncol. 2018 Feb 23. pii: S1470-2045(18)30116-5. doi: 10.1016/S1470-2045(18)30116-5.

De Placido S, Gallo C, De Laurentiis M,et al. GIM Investigators* (* … Di Lucca G…).